Mounjaro's maker has more room to run amid GLP-1 boom, Berenberg says

Berenberg upgraded Eli Lilly to buy from hold and raised its price target to $1,400 from $1,220, implying 23% upside from Monday's close. The firm expects Lilly to sustain its obesity-market leadership and sees upside to FY2026 guidance, supported by demand for GLP-1 drugs and the anticipated diabetes approval of oral GLP-1 Foundayo. Lilly shares have gained 52% over the past year and rose more than 1% premarket following the upgrade.

Analysis

The investable question is no longer whether LLY can grow obesity revenue, but whether it can sustain premium valuation while funding capacity, launch execution, and business-development spend. An oral entrant could expand the treated population materially by lowering needle aversion and potentially easing primary-care prescribing, but it also risks shifting mix toward a lower-net-price product; the key monitor is incremental gross profit per patient rather than prescription growth alone. Near term, an approval catalyst is likely more important for sentiment than earnings, as payer coverage and formulary placement determine the conversion of demand into revenue over the following 2-4 quarters.

Competitive dynamics favor LLY if oral efficacy, tolerability, and supply availability support switching from Novo Nordisk (NVO), but the market may be underestimating the response: NVO's oral franchise and next-generation obesity pipeline can force rebates, raising the probability that category revenue outgrows profits. The more consequential downside is reimbursement tightening—commercial and PBM coverage decisions can quickly move net pricing, while government coverage expansion would be structurally positive but slower and politically contingent. High consensus ownership means even a modest miss in volume, realized price, or capacity commentary could drive multiple compression disproportionate to the underlying earnings revision.

The external-pipeline argument should not receive full credit until acquisitions or licensing deals reveal price discipline. Obesity-generated cash flow can create genuine diversification, but it can also encourage late-cycle biotech M&A at elevated premiums; monitor deal size, contingent-value-right structure, and return thresholds. Over 6-18 months, differentiated cardiometabolic outcomes data and manufacturing utilization—not another sell-side target increase—are the variables most likely to determine whether LLY retains its scarcity premium.

Key Decisions for Investors

• Maintain a tactical long LLY only on pullbacks or through defined-risk call spreads, rather than chase an analyst-driven move. A 3-6 month bull call spread can target approval/formulary catalysts while limiting exposure to a crowded-positioning reset; invalidate if management lowers obesity volume or net-price expectations at the next earnings update.
• Use LLY versus NVO as a catalyst pair trade: long LLY / short NVO in roughly beta-neutral dollar amounts for the 1-3 month approval and early-access window. The thesis is relative oral-launch execution and US supply positioning, not absolute GLP-1 demand; exit if NVO announces superior efficacy data, meaningfully improved supply, or a more favorable payer-access trajectory.
• Do not underwrite the 2026 upside case until tracking three data points: prescription persistence after 90 days, gross-to-net trends by payer channel, and manufacturing-capacity commentary. Strong scripts without stable persistence or net price are an alert, not confirmation of incremental EPS power.
• For broader portfolio hedging, own a modest NVO position or healthcare exposure against an LLY overweight rather than treating the obesity market as winner-take-all. A reimbursement shock or category-wide price concession would impair both names, but relative share gains can preserve the LLY/NVO spread thesis.